Interfant-99 protocol Outcome of congenital acute lymphoblastic leukemia treated on the
暂无分享,去创建一个
R. Pieters | L. Silverman | M. Valsecchi | T. Leblanc | A. Möricke | J. Rubnitz | A. Vora | T. Szczepański | A. Biondi | A. Ferster | I. Hann | L. Hovi | G. Janka | M. Campbell | M. Felice | P. D. Lorenzo | Marieke H. van der Linden
[1] R. Pieters,et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial , 2007, The Lancet.
[2] N. Heerema,et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. , 2006, Blood.
[3] C. Pui,et al. Treatment of acute lymphoblastic leukemia. , 2006, The New England journal of medicine.
[4] G. Henze,et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials , 2005, Leukemia.
[5] A. Veerman,et al. Congenital leukaemia: the Dutch experience and review of the literature , 2002, British journal of haematology.
[6] S. Richards,et al. Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987–1999 , 2002, British journal of haematology.
[7] C. Pui,et al. Biological and therapeutic aspects of infant leukemia. , 2000, Blood.
[8] A. Borkhardt,et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. , 1999, Blood.
[9] N. Heerema,et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. D. Boer,et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia–implications for treatment of infants , 1998, Leukemia.
[11] J. Shuster,et al. Intensive Alternating Drug Pairs After Remission Induction for Treatment of Infants With Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Pilot Study , 1998, Journal of pediatric hematology/oncology.
[12] R. Gelber,et al. Intensified therapy for infants with acute lymphoblastic leukemia , 1997, Cancer.
[13] M. Greaves,et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[14] W. Hiddemann,et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. , 1994, Blood.
[15] Y. Bertrand,et al. Improved survival for acute lymphoblastic leukaemia in infancy: the experience of EORTC‐Childhood Leukaemia Cooperative Group , 1994, British journal of haematology.
[16] M. Valsecchi,et al. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies. , 2006, Haematologica.
[17] R. Pieters. Biology and Treatment of Infant Leukemias , 2003 .
[18] L. Frankel,et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). , 1997, Journal of pediatric hematology/oncology.
[19] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .